Di Yi Cai Jing·2025-12-19 01:58Group 1 - The company has entered a dual presidency phase with the appointment of Dr. Wang Lai as the new president, alongside the existing president, Dr. Wu Xiaobin [1][3] - Dr. Wang will oversee the company's research and development, business development, and alliance management functions [1] - Dr. Wu will continue in his role as president and COO, responsible for global commercialization, production, and supply chain operations [3] Group 2 - Dr. Wang is a key figure in the company, having led the development of the BTK inhibitor, Zebutinib, which is projected to generate $2.6 billion in sales in 2024, ranking 20th in global oncology drug sales [3] - The success of Zebutinib is attributed to both its therapeutic breakthroughs and effective commercialization strategies [3] - The collaboration between Dr. Wang's R&D team and Dr. Wu's commercialization team has been noted as highly effective [3]